AcelRx Pharmaceuticals Inc (R5XA.MU)
Munich - Munich Delayed price. Currency in EUR
Add to watchlist
As of 08:05AM CEST. Market open.
| Previous close | 0.9450 |
| Open | 0.7410 |
| Bid | 0.7110 x N/A |
| Ask | 0.7400 x N/A |
| Day's range | 0.7410 - 0.7410 |
| 52-week range | 0.4405 - 1.3300 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Insider Monkey
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q3 2023 Earnings Call Transcript
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q3 2023 Earnings Call Transcript November 9, 2023 Operator: Welcome to the AcelRx third quarter 2023 financial results conference call. This call is being webcasted live via the events page of the Investors section of AcelRx’s website at www.acelrx.com. This call is property of AcelRx, and any recording, reproduction or transmission […]
- Zacks
What Makes AcelRx Pharmaceuticals (ACRX) a New Buy Stock
AcelRx Pharmaceuticals (ACRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- Zacks
AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Tops Revenue Estimates
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 22.64% and 216.25%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
© 2024 Yahoo. All rights reserved.